Cephalon Off-Label Marketing

Issue: Alleged unlawful off-label marketing

United States ex rel. Matthew Cestra v. Cephalon, No. 14-01842 (E.D. Pa.); United States ex rel. Bruce Boise, et al. v. Cephalon, No. 08-287 (E.D. Pa.)

Lieff Cabraser, with co-counsel, represented four whistleblowers bringing claims on behalf of the U.S. Government and various states against Cephalon, Inc., a pharmaceutical company.

Relators alleged that Cephalon engaged in improper or off-label marketing of a cancer drug and two wakefulness drugs. Motions to dismiss were denied in large part and the cases proceeded to discovery before resolving via settlement in 2017.